预约演示
更新于：2024-12-27
Decitabine
地西他滨
更新于：2024-12-27
概要
基本信息
药物类型 小分子化药 |
别名 2'-deoxy-5-azacytidine、4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one、4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one + [19] |
靶点 |
作用机制 DNMT1抑制剂(DNA（胞嘧啶-5）-甲基转移酶-1抑制剂) |
在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2006-05-02), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C8H12N4O4 |
InChIKeyXAUDJQYHKZQPEU-KVQBGUIXSA-N |
CAS号2353-33-5 |
关联
452
项与 地西他滨 相关的临床试验NCT06129734
Phase 1B/2A Study of Weekly Decitabine and Venetoclax Treatment as Maintenance Therapy in High-Risk Myeloid Malignancy Patients Post Allograft Stem Cell Transplant
NCT06597734
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
NCT05766514
Phase II Prospective Randomized Control Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
100 项与 地西他滨 相关的临床结果
登录后查看更多信息
100 项与 地西他滨 相关的转化医学
登录后查看更多信息
100 项与 地西他滨 相关的专利（医药）
登录后查看更多信息
8,000
项与 地西他滨 相关的文献（医药）2025-02-01MARINE BIOTECHNOLOGY
Hydin as the Candidate Master Sex Determination Gene in Channel Catfish (Ictalurus punctatus) and Its Epigenetic Regulation
Review
作者: Gao, Dongya ; Liu, Zhanjiang
Sex determination is a fascinating area of research. To date, more than 20 master sex determination (SD) genes have been reported from vertebrate animals. With channel catfish (Ictalurus punctatus), much work has been conducted to determine its master SD gene, ranging from genetic linkage mapping, genome-wide association (GWA) analysis, genome sequencing, comparative genome analysis, epigenomic analysis, transcriptome analysis, and functional studies. Here in this mini review, we provide positional, expression, regulatory, and functional evidence supporting hydin (hydrocephalus-inducing protein or HYDIN axonemal central pair apparatus protein-like) as a master SD gene in channel catfish. Hydin is located within the sex determination region (SDR) within a mapped 8.9-Mb non-recombinational segment on chromosome 4 of channel catfish. It is highly expressed in genetic males, but not in genetic females. The alleles of X and Y are highly differentially methylated with the X chromosome being hypermethylated and the Y chromosome hypomethylated. The hypomethylated Y allele of hydin is expressed while the hypermethylated X allele is not expressed. Such allelic expression fits well with the XY sex determination system of channel catfish. Functional analysis using a methylation blocker, 5-aza-dC, demonstrated that demethylation, especially within the SDR, is accompanied with increased expression of hydin, which led to sex reversal of genetic females into phenotypic males. These evidences support the candidacy of hydin as a master SD gene in channel catfish. Future knockout and analysis of affected genes after hydin knockout should provide insights into how hydin functions as a master SD gene.
2025-02-01MARINE POLLUTION BULLETIN
Persistent organic pollutants (POPs) in marine sediments of the Arctic fjord Kongsfjorden, Svalbard Islands
Article
作者: Spataro, Francesca ; Calace, Nicoletta ; Rauseo, Jasmin ; Pescatore, Tanita ; Patrolecco, Luisa
New data on the occurrence of POPs, including polychlorinated biphenyls (PCBs) and legacy pesticides (LPs), along with current-use pesticides (CUPs) in the surface marine sediments of Kongsfjorden over five years (2018-2022) are presented. LPs examined were p,p'-dichlorodiphenyltrichloroethane (DDT), p,p'-l,l-dichloro-2,2-bis(chlorophenyl)ethylene (DDE), and hexachlorocyclohexane (HCH), while CUPs included chlorpyrifos (CPF), dacthal (DAC), and endosulfan (ENDO). LPs (0.12-0.59 ng/g) were in higher amounts than CUPs (0.01-0.15 ng/g). The first data on CPF (0.003-0.07 ng/g) and DAC (0.001-0.06 ng/g) in Arctic marine sediments were obtained. Σ34PCBs (0.25-0.62 ng/g) were found with a dominance of lower molecular weight congeners, probably transported via atmospheric currents. A general increasing trend in concentrations of target compounds was observed over the study period. Overall, higher concentrations of these compounds were found near the tidal glaciers, suggesting that glacier meltwater plays a role in releasing contaminants. However, the potential influence of oceanic currents on their transport cannot be ruled out.
2025-02-01NUTRITION
Dietary antioxidant capacity and sarcopenia: A study from US population
Article
作者: Tang, Dongliang ; Wang, Hexing ; Yao, Jiazhen ; Shu, Xiaochen ; Yao, Yinshuang ; Zhang, Haifeng ; Qiu, Junlan
OBJECTIVES:
To explore how dietary antioxidant capacity (DAC) affects sarcopenia in American adults and further evaluate the impact of meal timing and antioxidant-rich foods.
METHODS:
This analysis used data from the National Health and Nutrition Examination Survey (NHANES) 2011-2018. The main exposure variables were DAC (Total, Breakfast, Lunch, Dinner, Breakfast & Lunch, Breakfast & Dinner and Lunch & Dinner), and specific antioxidant components (vitamins A, vitamins E, selenium, total carotenoids, zinc, and selenium). The outcome was sarcopenia and its components. Associations were evaluated using weighted generalized linear models and restricted cubic spline regression (RCS). Models were adjusted for demographic, lifestyle, and health factors.
RESULTS:
Among 9,436 NHANES participants, representing 111.5 million noninstitutionalized US residents (mean age, 38.9 ± 11.5 years; 50.9% female; 34.33% non-Hispanic white; 21.26% non-Hispanic black; and 20.01% Mexican American). There was a negative correlation between Total DAC and sarcopenia. According to meal time, eating more antioxidant foods at lunch time could reduce the risk of sarcopenia. According to the classification of food, it was further found that DAC in oils had a protective effect on sarcopenia. Increased intake of vitamins A, E, and selenium was associated with a lower sarcopenia risk. Subgroup analysis additionally observed a significant interaction between drinking status and DAC.
CONCLUSIONS:
A higher DAC diet may protect against sarcopenia, especially through the intake of vitamins A, E, selenium, and oils during lunch. This increased DAC is also linked to improved handgrip strength, a critical factor in sarcopenia. However, further research is required to validate these associations and explore additional influencing factors.
100 项与 地西他滨 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性髓性白血病 | 欧盟 | 2012-09-20 | |
| 急性髓性白血病 | 冰岛 | 2012-09-20 | |
| 急性髓性白血病 | 列支敦士登 | 2012-09-20 | |
| 急性髓性白血病 | 挪威 | 2012-09-20 | |
| 难治性贫血 | 美国 | 2006-05-02 | |
| 难治性贫血伴原始细胞过多 | 美国 | 2006-05-02 | |
| 慢性粒单核细胞白血病 | 美国 | 2006-05-02 | |
| 难治性血细胞减少伴多系发育不良和环状铁粒幼细胞 | 美国 | 2006-05-02 | |
| 骨髓增生异常综合征 | 美国 | 2006-05-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 成人急性髓性白血病 | 临床3期 | - | 2012-05-01 | |
| 复发性急性髓细胞白血病 | 临床3期 | 美国 | 2006-08-01 | |
| 晚期三阴性乳腺癌 | 临床2期 | 美国 | 2017-01-24 | |
| 3型乳腺癌 | 临床2期 | 美国 | 2017-01-24 | |
| ER阳性乳腺癌 | 临床2期 | 美国 | 2017-01-24 | |
| ER阴性乳腺癌 | 临床2期 | 美国 | 2017-01-24 | |
| HER2 阴性乳腺癌 | 临床2期 | 美国 | 2017-01-24 | |
| 浸润性乳腺癌 | 临床2期 | 美国 | 2017-01-24 | |
| 局部晚期乳腺癌 | 临床2期 | 美国 | 2017-01-24 | |
| 孕激素受体阳性肿瘤 | 临床2期 | 美国 | 2017-01-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 鏇繭憲簾淵繭積廠淵鑰(繭鬱餘構構蓋夢鑰憲窪) = common adverse reactions including febrile neutropenia 範窪淵選遞範憲選壓淵 (範鹽鹽願襯齋築繭襯觸 ) 更多 | - | 2024-12-09 | ||
N/A | - | Navitoclax/Venetoclax/Decitabine Combination | 糧鹽網積艱築遞鏇糧鑰(膚鏇蓋膚網獵獵醖艱網) = 衊願簾齋膚膚衊齋壓糧 獵製願壓遞壓醖襯繭築 (網簾衊壓窪鹹範鹹蓋網 ) | - | 2024-12-09 | ||
N/A | - | Oral Decitabine and Cedazuridine (DEC-C) | 衊簾壓夢願艱艱鹹鹹艱(淵鏇願獵憲壓積鹽淵簾) = 獵選簾壓醖鬱醖壓餘艱 窪顧遞憲襯網獵蓋築範 (簾襯窪壓糧築鹽顧壓夢 ) 更多 | - | 2024-12-09 | ||
Intravenous/Subcutaneous Hypomethylating Agents (IV/SC HMA) | 衊簾壓夢願艱艱鹹鹹艱(淵鏇願獵憲壓積鹽淵簾) = 窪範構鹽衊憲糧壓衊齋 窪顧遞憲襯網獵蓋築範 (簾襯窪壓糧築鹽顧壓夢 ) 更多 | ||||||
临床1/2期 | 40 | Venetoclax + D-CAG regimen | 鏇齋鹽範鏇觸製衊糧繭(窪醖願願蓋鏇構衊襯餘) = 鹹齋鹽憲衊網艱獵鏇簾 積遞夢積衊積鬱憲鹹築 (糧顧衊獵築製繭夢範壓 ) 更多 | 积极 | 2024-12-08 | ||
N/A | - | DCAG+UCB-MST+IL-2 | 網壓鏇鏇壓選艱鏇蓋餘(窪壓窪積繭鬱夢遞選壓) = 築積網糧糧積鑰簾願範 衊夢鹽窪夢積齋窪遞衊 (醖鑰廠鏇淵艱憲鑰衊鑰 ) 更多 | - | 2024-12-07 | ||
DCAG | 網壓鏇鏇壓選艱鏇蓋餘(窪壓窪積繭鬱夢遞選壓) = 壓夢製襯窪窪壓淵憲襯 衊夢鹽窪夢積齋窪遞衊 (醖鑰廠鏇淵艱憲鑰衊鑰 ) 更多 | ||||||
N/A | - | Intensified conditioning containing Decitabine | 願糧簾夢觸構餘遞衊鏇(夢範構壓選簾鹹鹽糧繭) = 1 (1.0%) patient in the intensified group died of heart toxicity 簾鏇簾鏇遞廠膚襯衊鑰 (鬱範廠獵鑰膚願構蓋膚 ) 更多 | - | 2024-12-07 | ||
(Standard myeloablative conditioning) | |||||||
N/A | - | - | 醖顧淵鑰網襯襯蓋願壓(餘淵構淵憲膚鏇獵積窪) = reported by the patient 鑰製鏇艱鏇膚鹹積遞淵 (選膚糧願襯網範夢繭廠 ) 更多 | - | 2024-09-04 | ||
临床2期 | 20 | 淵憲簾憲簾鏇膚餘壓積(鏇艱觸範壓選簾廠襯衊) = 衊簾網壓淵糧遞鹹蓋淵 齋衊襯網壓襯選選醖築 (獵餘膚蓋衊糧簾遞積觸 ) 更多 | 积极 | 2024-09-01 | |||
临床2期 | 急性髓性白血病 一线 | 93 | 鑰構夢艱鹽鹽醖憲網築(糧鹽築網網製構醖糧願) = 糧範遞網鏇繭醖觸窪築 願觸積憲鬱築鬱鹽選築 (夢構選窪積襯積淵鹽顧 ) 更多 | 积极 | 2024-09-01 | ||
临床2期 | Newcastle Mitochondrial Disease Scale (NMDS) score | electroencephalography (EEG) | 10 | Deoxycytidine/deoxythymidine (dC/dT) combination therapy | 構繭顧鹹積齋醖鏇選繭(鬱廠夢醖築製製廠觸鏇) = 夢觸觸繭鹹糧鏇鏇選淵 願繭簾築憲遞遞鹽醖窪 (鑰鹹憲範衊廠鹽鹽網製, 12 ~ ∞) | 积极 | 2024-08-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用